Further to its intimation dated 30th April, 2021, Caplin Point has informed that the Board of Directors the Company at its meeting held on 6th May 2021 has, took note/ approved the following: Declared an Interim Dividend of Rs 1.50 (75%) per equity share of Rs 2 each for the financial year ended 31st March 2021, fixed 19th May 2021 as Record Date for determining the eligibility of the Shareholders for the purpose of Interim Dividend, approved the Audited standalone and consolidated financial results (Annexure-1) of the Company as per Indian Accounting Standards for the year ending 31st March, 2021 along with Auditors Report (Annexure-2). It has enclosed a Press Release issued by the Company (Annexure 3) and an investor presentation in this regard (Annexure), retirement of R Ravichandran (DIN: 01920603), Independent Director of the Company effective 11th May 2021 (Close of Business hours) upon completion of his tenure, appointment of Dinesh R G (ACS 42539) as the Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with effect from 6th May 2021. (Annexure-5) and Incorporation of a wholly owned subsidiary in India namely Caplin Onco for carrying out Oncology specific business. The company has confirmed and declared that the Statutory Auditors of the Company, CNGSN & Associates LLP, Chartered Accountants, Chennai, have issued the audit report on Standalone and Consolidated Financial Statements of the Company for the year ended 31st March, 2021 with unmodified opinion. The meeting commenced at 10.30 am and concluded at 12.35 pm.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: